On March 12, 2026, Pulse Biosciences, Inc. announced the first patient enrollments in a clinical study evaluating its Vybrance™ system for treating papillary thyroid microcarcinoma. The study aims to assess the safety and effectiveness of this innovative technology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.